Clinical Trial

DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated May 10, 2024 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
A Clinical Study to Evaluate the Efficacy and Safety of DP303c versus trastuzumab emtansine in patients with HER2-positive Advanced Breast Cancer
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-03-14.
Status change: Not Yet Recruiting → Recruiting 2024-05-08
Trial Details
NCT Number NCT06313086
Lead Sponsor CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Conditions HER2-positive Breast Cancer
Enrollment 442 participants
Start Date 2024-03-13
Primary Completion 2025-12 (estimated)
Study Completion 2028-02 (estimated)
Updated on ClinicalTrials.gov 2024-05-10